Diligence memo · auto-generated · as of July 2, 2026
Dosentrx Ltd.
Dosentrx Ltd. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Dosentrx Ltd. operates in Pharmaceuticals, based in MODIIN MACCABIM REUT.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Dosentrx Ltd. has raised $1.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.8M on 2026-02-18.
Most recent recorded round closed around 2026-02-18.
Valuation (modeled)modeled
Provath models Dosentrx Ltd. at approximately $3.6M (range $1.3M–$6.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.59× the median modeled value of Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era. Issuer reports $1M–$5M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Last raise 4 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 26% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Kairos Pharma, LTD., Branch Therapeutics, Inc., ResBiotic Nutrition, Inc., Califia Pharma, Inc., BTB Therapeutics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.